PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
04-Aug-2023 Newron announces H1 2023 results and provides R&D update Newron Pharmaceuticals S.p.A.
04-Aug-2023 H1 2023 result outperforms prior year at constant exchange rates COLTENE Holding AG
03-Aug-2023 Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023 MorphoSys AG
03-Aug-2023 Drug development consultancy launches new regulatory operations service Boyds
03-Aug-2023 £330K grant awarded to support and engage patients at risk of MND/ALS, and track psychological impact of genetic testing Sano Genetics
03-Aug-2023 LATEST FINDINGS ON RARE DISEASE OF THE INNER EAR Karl Landsteiner University of Health Sciences
03-Aug-2023 Innovative Trials shortlisted for prestigious British Business Excellence Award Innovative Trials
03-Aug-2023 Life Science People secures £4 million of new investment from Silchester Partners Ltd as its global growth plans accelerate. Life Science People
03-Aug-2023 Moberg Pharma´s Interim report January - June 2023 Moberg Pharma
03-Aug-2023 TRYP THERAPEUTICS ANNOUNCES JASON CARROLL AS NEW CHIEF EXECUTIVE OFFICER Tryp Therapeutics Inc.
03-Aug-2023 Invitation: Straumann Group 2023 half-year results webcast Straumann Holding AG
03-Aug-2023 Samanta Cimitan Appointed Chief Executive Officer (CEO) at Celonic B3C newswire
02-Aug-2023 Publication of new data demonstrates significantly superior efficacy of XF-73 compared to a leading topical antibiotic against MRSA in skin infection models Destiny Pharma plc
02-Aug-2023 Zuellig Pharma Singapore and GSK Establish Vaccine Distribution Hub to Improve Asia’s Access to Vaccines Zuellig Pharma
02-Aug-2023 TOUCH INDEPENDENT MEDICAL EDUCATION OPENS OFFICE IN THE US Touch Independent Medical Education (touchIME)
02-Aug-2023 WITH GREAT SADNESS TRYP ANNOUNCES THE PASSING OF DAVID TOUSLEY, DIRECTOR Tryp Therapeutics Inc.
02-Aug-2023 Epigenomics AG: Capital reduction planned at a ratio of 5 : 1 Epigenomics AG
01-Aug-2023 Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology Zenas BioPharma
01-Aug-2023 ATS PACKAGING TAKES CENTRE STAGE AT PPMA SHOW 2023 ATS PACKAGING
01-Aug-2023 CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK CureVac